[ad_1]
PHOENIX, Feb. 26, 2022 /PRNewswire-PRWeb/ — A patient-activated, reliever-triggered inhaled glucocorticoid strategy, combined with usual care, reduces asthma exacerbations and improves asthma control and quality of life in African American and Hispanic/Latinx adult patients with poorly controlled asthma. The results of the Person Empowered Asthma Relief (PREPARE) trial are being presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) and are being simultaneously published in The New England Journal of Medicine.
The resulting paper, Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma, funded by the Patient Centered Outcomes Research Institute through a grant to the Brigham and Women’s Hospital, compared the addition of a patient-activated reliever-triggered inhaled
glucocorticoid strategy (hereafter referred to as intervention group) to usual care alone. The real-world study recruited 603 African American and 598 Hispanic/Latinx patients with clinically diagnosed asthma, aged 18-75 years old. The study was conducted in primary care and specialty practices across the continental United States and in Puerto Rico.
Patients who were recruited had to meet one of the following stipulations: be prescribed daily inhaled glucocorticoids with or without long-acting β2-agonist (LABA) and an Asthma Control Test (ACT) score of 19 or lower, which indicates asthma is not well controlled, or an asthma exacerbation leading to overnight hospitalization or use of systemic glucocorticoids within the past year. The annualized rate of severe asthma exacerbations was used as the primary …
Full story available on Benzinga.com
[ad_2]
Source link
